JinRui Foundation Biotechnology Co., Ltd Granted IND in China
Release time：2020-11-06 09:18:42 Reading：
JinRui Foundation Biotechnology Co., Ltd (JRF) announced today that they will be proceeding with clinical trials of JRF-103, a drug for treating advanced solid tumors, after receiving an Investigational New Drug (IND) designation from the Center for Drug Evaluation (CDE), China.
JRF developed a new irreversible pan-HER kinase inhibitor, JRF-103, with significant inhibitory activity against HER1, HER2, HER4 receptors and EGFR with L858R, T790M, and L858R & T790M mutations. JRF-103 is expected to treat tumors with EGFR/HER2 Exon20ins, where no targeted drug has been approved before. “We are very pleased that JRF’s IND approval has been granted for such an innovative approach on treating advanced solid tumors, especially targeting EGFR/HER2 Exono20ins,” said Xintian Lai, Chairman at JRF. “No drug has been approved specifically for EGFR/HER2 Exon20ins, and therefore, the huge clinical and market needs have not been met yet.” “JRF is excited by the potential of the innovative drug to treat various tumors, such as lung cancer, breast cancer, gastric cancer, and colorectal cancer,” said Tianmin Zhu, President & CEO at JRF. “We are looking forward to investigating this unprecedented treatment in China.”
About JRF
JRF is an international biotechnology company that focuses on innovative drugs and R&D platforms. The company was founded in 2009 and is headquartered in Chengdu, China. JRF’s long-term strategy is to become a key player in oncology. Currently, JRF’s molecular entities in clinical development target glioma, lung cancers, and other solid tumors, as well as various hematologic malignancies. This portfolio of innovative drugs is being developed with partners across the world. For more information, please visit www.jrfbio.com.
